**RESULT REPORT Q1 FY25** | Sector: Building Materials

# **Apollo Pipes Ltd.**

### Standalone volumes flat, maintain ADD!

#### **Result Synopsis**

Apollo Pipes Ltd (standalone) volumes remained flattish at 20,937Te (2-year volume CAGR stood at 20%). The volumes were flattish owing to lower demand for HDPE pipes which constituted ~15% of volumes in previous quarter and the same in Q1FY25 was <5%. However ex-HDPE, plastic pipe volumes grew by 10%YoY. Standalone EBITDA/Te stood at Rs11.6 as compared to 12.3/12.1 in Q1FY24/Q4FY24 respectively. In Q1FY25, company consolidated the performance of Kisan Mouldings (subsidiary) which was acquired in Q4FY24 to expand the presence in west India. Kisan volumes stood at 5,625Te and the same turned profitable (after FY20) with EBITDA of Rs50Mn on account of change in product-mix towards fittings.

Management believes that with improving demand, Apollo's revenue should grow by 25%YoY in FY25E and Kisan should contribute incremental Rs4-5Bn. With new Varanasi plant of 30,000Te which is expected to commence operations from Q4FY25, O-PVC pipes, windows & doors coupled with brownfield expansion of 28,500Te, company aims to reach a turnover of Rs26Bn by FY27E. Apollo's standalone EBITDA margins are likely to remain capped at ~10% owing to higher capex cost, Kisan's margins will improve gradually to 10% with better product mix and higher utilizations.

We have incorporated Kisan Mouldings contribution to our overall estimates. Hence, we expect revenue growth of 40% for FY25E wherein Apollo's standalone biz is likely to grow by 12%YoY. Over FY24-FY26E, we reckon Revenue/EBITDA/PAT to grow by 33%/31%/40% respectively. We believe operating margins will be ~9.5% over similar period. At CMP, the stock trades at P/E(x) of 31x on FY26E EPS of 20.2 (adjusted for revised share capital), we continue to value the company at P/E(x) of 35x on FY26E EPS, arriving at a target price of Rs709. Hence, we maintain our ADD rating on the stock.

#### **Result Highlights**

- Standalone revenue stood at Rs2.40Bn, a decline of 8%YoY & 7% below estimates (2-year CAGR stood at 5%).
- EBITDA margins (standalone) came in at 10.1% which was similar to Q1FY24 & Q4FY24 margins. Absolute EBITDA, declined by 7%YoY.
- Net profit (standalone) declined by 22%YoY to Rs109Mn, on account of higher depreciation and finance cost.
- Q1FY25 consol nos include the acquisition of Kisan Mouldings which is now a subsidiary of APOLLO PIPES Ltd. Owing to the same, Q4FY24 & FY24 numbers have been revised and only 5-6days of operations have been consolidated. Hence the Q1FY25 Vs Q4FY24 consol numbers are not comparable.

**Exhibit 1: Actual vs estimates** 

Rs mn	Actual	Estimate		% <b>V</b> a	Remarks	
ks mn Actuai		YES Sec	Consensus	YES Sec	Consensus	Remarks
Sales	2,402	2,580	2,793	(6.9)	(14.0)	
EBITDA	243	258	273	(5.5)	(10.9)	Revenue below
EBITDA Margin (%)	10.1	10.0	9.8	15 bps	35 bps	estimates but margin in-line.
Adjusted PAT	109	114	134	(4.3)	(18.8)	iii iiiic.

Source: Company, YES Sec



Reco	: ADD
СМР	: Rs 623
Target Price	: Rs 709
Potential Return	: +13.8%

#### Stock data (as on Jul 30, 2024)

Nifty	24,857
52 Week h/I (Rs)	799 / 588
Market cap (Rs/USD mn)	25,325 / 303
Outstanding Shares (mn)	41
6m Avg t/o (Rs mn):	66
Div yield (%):	-
Bloomberg code:	APOLP IN
NSE code:	APOLLOPIPE

#### Stock performance



#### Shareholding pattern (As of Jun'24 end)

Promoter	45.9%
FII+DII	21.3%
Others	32.8%

#### ∆ in stance

(1-Yr)	New	Old
Rating	ADD	ADD
Target Price	709	745

#### $\Delta$ in earnings estimates

	FY25E	FY26E
EPS (New)	15.6	20.2
EPS (Old)	16.2	21.3
% change	-3.6%	-5.0%

#### Financial Summary

(Rs mn)	FY24	FY25E	FY26E
Net Revenue	9,870	13,744	17,385
YoY Growth	7.9	39.3	26.5
EBIDTA	958	1,305	1,633
EBIDTA (%)	9.7	9.5	9.4
PAT	428	646	836
YoY Growth	77.9	50.9	29.4
ROE	8.3	8.8	8.9
EPS	10.9	15.6	20.2
P/E	63.0	39.9	30.8
BV/Share	146	217	237
P/BV	4.7	2.9	2.6

UDIT GAJIWALA Lead Analyst udit.gajiwala@ysil.in



SHALIN DAMANI, Associate



#### **Operational Highlights for Q1FY25**

- Standalone volumes for the quarter stood at 20,937Te, flattish on a YoY & QoQ basis (2-year volumes CAGR stood at 21%).
- ASP stood at Rs115/Te as compared to Rs123/Rs120 in Q1FY24/Q4FY24, respectively.
- EBITDA/Te came in at Rs11.6 Vs Rs12.3/Rs12.1 in Q1FY24/Q4FY24 respectively.

**Exhibit 2: Quarterly Snapshot (standalone):** 

Rs mn	Q4 FY23	Q1 FY24	Q2 FY24	Q3 FY24	Q4 FY24	Q1 FY25	% yoy	% qoq
Revenue	2,519	2,603	2,495	2,216	2,458	2,402	(7.7)	(2.3)
Expenditure	2,225	2,342	2,253	2,014	2,208	2,159	(7.8)	(2.2)
- RM	1,809	1,904	1,782	1,569	1,796	1,694	(11.0)	(5.7)
- Staff Cost	124	152	164	154	142	161	6.1	13.9
- Other cost	292	285	306	291	271	304	6.4	12.1
Operating Profit	295	262	242	201	249	243	(7.0)	(2.4)
OPM(%)	11.7	10.1	9.7	9.1	10.1	10.1	8 bps	-2 bps
Other Income	7	12	13	11	3	8	(29.9)	156.3
Depreciation	76	67	72	75	83	83	25.4	-
Interest	24	15	7	14	15	20	33.8	37.4
PBT	202	192	175	123	155	148	(22.9)	(4.3)
Tax	51	53	46	33	89	39	(25.5)	(56.0)
PAT	151	139	129	91	66	109	(21.9)	66.0

Source: Company, YES Sec

#### **Exhibit 3: Operational Numbers (standalone):**

Particulars	Q4 FY23	Q1 FY24	Q2 FY24	Q3 FY24	Q4 FY24	Q1 FY25	% yoy	% qoq
Volumes (Te)	18,685	21,219	19,803	18,868	20,550	20,937	(1.3)	1.9
Realization (Rs/Te)	135	123	126	117	120	115	(6.5)	(4.1)
EBITDA/Te	15.8	12.3	12.2	10.7	12.1	11.6	(5.8)	(4.2)

Source: Company, YES Sec

#### Exhibit 4: Q1FY25 Snapshot (consolidated):

Rs mn	Apollo Pipes	Kisan Mouldings	Total
Volumes (Te)	20,937	5,625	26,562
Realization (Rs/Te)	115	121	116
Revenue	2,402	683	3,085
Expenditure	2,159	636	2,795
- RM	1,694	468	2,162
- Staff Cost	161	72	234
- Other cost	304	96	400
Operating Profit	243	46	290
OPM(%)	10.1	6.8	9.4
Other Income	8	2	10
Depreciation	83	16	99
Interest	20	2	22
PBT	148	30	178
Tax	39	0	39
PAT	109	30	139
PAT(%)	4.5%	4.4%	4.5%




### **KEY CON-CALL HIGHLIGHTS**


- Guidance: Company reiterated revenue guidance of 25-30%CAGR for the next 3-4 years to Rs26Bn by FY27E where standalone revenue would be Rs 16Bn, Kisan would contribute Rs7-8Bn and windows & O-PVC would contribute the remaining. Blended margin would remain at ~10% for the next 2-3 years and will increase to ~12-13% after the 286,000Te capacity is fully operational. ROCE guidance retained at 25-30% over the same period.
- Company expects revenue of Rs12-12.5Bn from Apollo standalone and Rs4-5Bn from Kisan, taking the total to ~Rs16.5-17.5Bn for FY25E.
- Volumes for the quarter were flat due to ongoing election season. Owing to which the HDPE pipes which contributed ~15% of volumes, contracted to mere 5%. Ex-HDPE, pipes volumes for the company increased by 10%.
- Currently dealers are working with low-inventory. However with stability in resin prices, management expects dealers to resort to re-stocking.
- Kisan Mouldings: Kisan recorded Rs680Mn revenue in Q1FY25 and an EBITDA of Rs50Mn (turned profitable). Company expects similar 7-8% margin for FY25E and the same will increase to 10-12% by FY27E. Company does not foresee any incremental investment in this subsidiary.
- Capex: Total capex of Rs2.5Bn for the OPVC (Rs1Bn, 50% incurred), Varanasi plant (Rs1.5Bn) and window profile (Rs0.6Bn, 10% incurred), most of which would be incurred in FY25E. For the next 2-3 years company expects a capex outlay of Rs1-1.5Bn each year for residual capex plus South India expansion (under consideration). Entire capex will be funded from internal accruals and the pending fund infusion.
- Company started first line of OPVC pipes in Q1FY25 and the other 2 lines will be operational by Q4FY25 contributing 5% to total topline in FY25E & 8-10% FY26E onwards.
- 70-80% of the 30,000Te Varanasi plant capacity & complete window profile project is expected to be operational by Q4FY25E.
- Agri/Non-agri mix for Apollo is 45%/55%. Agri biz contributes 70% of Kisan's revenue.
- Capacity utilization is 55% for both Apollo & Kisan.
- Value-added products of CPVC pipes & water tanks recorded a growth of 20%YoY/30%YoY respectively.

## **QUARTERLY TRENDS**

Exhibit 5: Standalone pipe volumes were flattish YoY...

Exhibit 6: Realization came in at Rs115/kg...







Source: Company, YES Sec

Source: Company, YES Sec

Exhibit 7: Revenue declined by 8%YoY...

Exhibit 8: EBITDA/kg stood at Rs11.6...







Source: Company, YES Sec

Source: Company, YES Sec

#### Exhibit 9: Net Profit was Rs109Mn...

Exhibit 10: OPM & NPM came in at 10% & 4.5%...





Source: Company, YES Sec



### **FINANCIALS**

**Exhibit 11: Income Statement** 

Y/e 31 Mar (Rs mn)	FY22	FY23	FY24	FY25E	FY26E
Sales	7,841	9,145	9,870	13,744	17,385
COGS	5,732	6,927	7,136	10,131	12,753
COGS %sales	73.1	75.7	72.3	73.7	73.4
GP	2,109	2,218	2,733	3,612	4,633
GP%	26.9	24.3	27.7	26.3	26.6
EBITDA	934	681	958	1,305	1,633
EBITDA%	11.9	7.4	9.7	9.5	9.4
Depreciation	257	284	299	431	516
Finance Cost	43	89	51	63	63
Other Income	38	20	39	50	60
PBT	672	328	648	861	1,114
Tax	174	88	220	215	279
PAT	498	241	428	646	836
PAT%	6.3	2.6	4.3	4.7	4.8

Source: Company, YES Sec

**Exhibit 12: Balance Sheet** 

Y/e 31 Mar (Rs mn)	FY22	FY23	FY24	FY25E	FY26E
Share Capital	393	393	394	414	414
Reserves	3,660	4,179	5,347	5,993	6,829
Equity	4,053	4,572	5,740	8,956	9,792
Payables	550	1,179	1,669	2,370	2,983
Provisions	4	5	79	79	79
Other current Liab	415	364	881	881	881
Total Equity & Liab	5,438	6,619	10,106	14,022	15,471
Gross Block	3,017	3,746	6,105	8,105	8,905
Acc Dep	956	1,240	1,539	1,969	2,485
Net Block	2,061	2,506	4,567	6,136	6,420
CWIP	71	56	84	84	84
Other Noncurrent	154	453	1,344	1,344	1,344
Inventory	1,316	1,708	1,987	2,821	3,551
Receivables	705	658	796	1,108	1,401
Cash & Bank	418	348	560	1,761	1,902
Loans	57	38	36	36	36
Other	352	553	331	331	331
Total Assets	5,438	6,619	10,106	14,022	15,471



**Exhibit 13: Cash Flow** 

Y/e 31 Mar (Rs mn)	FY22	FY23	FY24	FY25E	FY26E
PBT	672	327	648	861	1,114
Depreciation & Amortization	257	284	299	431	516
Finance cost	43	89	51	63	63
(Incr)/Decr in Working Capital	(417)	146	444	(446)	(410)
Taxes	(158)	(143)	(180)	(215)	(279)
Cash from ops.	364	687	1,247	694	1,004
(Incr)/ Decr in PP&E	(423)	(728)	(957)	(2,000)	(800)
Cash Flow from Investing	(368)	(680)	(2,140)	(2,000)	(800)
(Decr)/Incr in Borrowings	(256)	51	(1,222)	-	-
Finance cost	(44)	(89)	(51)	(63)	(63)
Cash Flow from Financing	(300)	(78)	(637)	2,507	(63)
Incr/(Decr) in cash	(304)	(70)	(1,530)	1,201	141
Cash and cash equivalents at beginning of year	722	418	2,076	560	1,761
Cash and cash equivalents at end of year	418	348	546	1,761	1,902


Source: Company, YES Sec

**Exhibit 14: Ratios** 

Growth Matrix (%)         51.3         16.6         7.9         39.3         26.5           EBITDA growth         25.8         (27.1)         40.8         36.2         25.1           EBIT growth         9.9         (41.7)         67.7         32.3         27.4           PAT growth         11.9         (51.7)         77.9         50.9         29.4           Portitability ratios (%)           We margin         26.9         24.3         27.7         26.3         26.6           EBIT DA margin         11.9         7.4         9.7         9.5         9.4           EBIT margin         6.1         4.6         7.1         6.7         6.8           PAT margin         6.3         2.6         4.3         4.7         4.8           RoCE         18.1         9.5         12.2         10.9         11.2           RoE         12.2         5.6         8.3         8.8         20.2           EPS         12.7         6.1         10.9         15.6         20.2           EVPS         10.1         116.3         145.9         21.6         23.6           BVPS         13.4         4.7         2.9	Key Ratios	FY22	FY23	FY24	FY25E	FY26E
EBITDA growth         25.8         (27.1)         40.8         36.2         25.1           EBIT growth         9.9         (41.7)         67.7         32.3         27.4           PAT growth         11.9         (51.7)         77.9         50.9         29.4           Profitability ratios (%)           GP margin         26.9         24.3         27.7         26.3         26.6           EBIT Margin         9.1         4.6         7.1         6.7         6.8           PAT margin         6.3         2.6         4.3         4.7         4.8           RoCE         18.1         9.5         12.2         10.9         11.2           RoE         13.2         5.6         8.3         8.8         8.9           Per share values           EPS         12.7         6.1         10.9         15.6         20.2           CEPS         19.2         13.3         18.5         26.0         32.7           BVPS         10.1         116.3         145.9         216.6         236.8           Valuation ratios (x)           P/E         38.0         81.7         63.0         39.9         30.8     <	Growth Matrix (%)					
EBIT growth         9.9         (41.7)         67.7         32.3         27.4           PAT growth         11.9         (51.7)         77.9         50.9         29.4           Profitability ratios (%)           GP margin         26.9         24.3         27.7         26.3         26.6           EBIT margin         11.9         7.4         9.7         9.5         9.4           EBIT margin         9.1         4.6         7.1         6.7         6.8           PAT margin         6.3         2.6         4.3         4.7         4.8           RoCE         18.1         9.5         12.2         10.9         11.2           RoE         13.2         5.6         8.3         8.8         8.9           PER share values         20.2         10.2         10.9         15.6         20.2           EPS         12.7         6.1         10.9         15.6         20.2           EVES         19.2         13.3         18.5         26.0         32.7           BVPS         103.1         116.3         145.9         216.6         236.8           P/E         38.0         81.7         63.0         39.9	Revenue growth	51.3	16.6	7.9	39.3	26.5
PAT growth         11.9         (51.7)         77.9         50.9         29.4           Profitability ratios (%)         CP margin         26.9         24.3         27.7         26.3         26.6           EBIT Margin         11.9         7.4         9.7         9.5         9.4           EBIT margin         9.1         4.6         7.1         6.7         6.8           PAT margin         6.3         2.6         4.3         4.7         4.8           ROCE         18.1         9.5         12.2         10.9         11.2           RoE         18.1         9.5         12.2         10.9         11.2           RoE         18.1         9.5         12.2         10.9         11.2           RoE         18.1         9.5         12.2         10.9         11.2           Per share values         20.2         18.3         18.5         26.0         32.7           EPS         12.7         6.1         10.9         15.6         20.2           EPS         19.2         13.3         14.5         26.0         32.7           BVPS         30.3         81.7         63.0         39.9         30.8 <t< td=""><td>EBITDA growth</td><td>25.8</td><td>(27.1)</td><td>40.8</td><td>36.2</td><td>25.1</td></t<>	EBITDA growth	25.8	(27.1)	40.8	36.2	25.1
Profitability ratios (%)         26.9         24.3         27.7         26.3         26.6           EBITDA margin         11.9         7.4         9.7         9.5         9.4           EBIT margin         9.1         4.6         7.1         6.7         6.8           PAT margin         6.3         2.6         4.3         4.7         4.8           RoCE         18.1         9.5         12.2         10.9         11.2           RoE         13.2         5.6         8.3         8.8         8.9           Per share values         8         8.9         8.9         1.0         15.6         20.2           CEPS         19.2         13.3         18.5         26.0         32.7           BVPS         103.1         116.3         145.9         216.6         236.8           Valuation ratios (x)           P/E         38.0         81.7         63.0         39.9         30.8           EV/EBITDA         20.2         29.0         28.2         18.9         15.0           Leverage ratios (x)         9         0.0         0.0         0.1         0.1         0.1           Net debt/EgitDA         0.0	EBIT growth	9.9	(41.7)	67.7	32.3	27.4
GP margin         26.9         24.3         27.7         26.3         26.6           EBITDA margin         11.9         7.4         9.7         9.5         9.4           EBIT margin         9.1         4.6         7.1         6.7         6.8           PAT margin         6.3         2.6         4.3         4.7         4.8           RoCE         18.1         9.5         12.2         10.9         11.2           RoE         13.2         5.6         8.3         8.8         8.9           Per share values         8         8.9         8.9         10.2         10.9         15.6         20.2           CEPS         19.2         13.3         18.5         26.0         32.7         8.9         216.6         236.8	PAT growth	11.9	(51.7)	77.9	50.9	29.4
BITDA margin         11.9         7.4         9.7         9.5         9.4           EBIT margin         9.1         4.6         7.1         6.7         6.8           PAT margin         6.3         2.6         4.3         4.7         4.8           RoCE         18.1         9.5         12.2         10.9         11.2           RoE         13.2         5.6         8.3         8.8         8.9           Per share values         8         8.7         8.1         10.9         15.6         20.2           CEPS         19.2         13.3         18.5         26.0         32.7           BVPS         103.1         116.3         145.9         216.6         236.8           Valuation ratios (x)         7         4.3         4.5         2.6         236.8           P/E         38.0         81.7         63.0         39.9         30.8           P/B         4.7         4.3         4.7         2.9         2.6           EV/EBITDA         20.2         29.0         28.2         18.9         15.0           Leverage ratios (x)         0.1         0.1         0.1         0.1           Net debt/EpitDA	Profitability ratios (%)					
EBIT margin         9.1         4.6         7.1         6.7         6.8           PAT margin         6.3         2.6         4.3         4.7         4.8           RoCE         18.1         9.5         12.2         10.9         11.2           RoE         13.2         5.6         8.3         8.8         8.9           Per share values           EPS         12.7         6.1         10.9         15.6         20.2           CEPS         19.2         13.3         18.5         26.0         32.7           BVPS         103.1         116.3         145.9         216.6         236.8           Valuation ratios (x)           P/E         38.0         81.7         63.0         39.9         30.8           EV/EBITDA         20.2         29.0         28.2         18.9         15.0           Leverage ratios (x)         20.2         29.0         28.2         18.9         15.0           Debt/ Equity         0.1         0.1         0.1         0.1         0.1           Net debt/EBITDA         (0.0)         0.0         0.0         (0.1)         (0.1)           Net debt/EBITDA         (0.0)	GP margin	26.9	24.3	27.7	26.3	26.6
PAT margin         6.3         2.6         4.3         4.7         4.8           RoCE         18.1         9.5         12.2         10.9         11.2           RoE         13.2         5.6         8.3         8.8         8.9           Per share values           EPS         12.7         6.1         10.9         15.6         20.2           CEPS         19.2         13.3         18.5         26.0         32.7           BVPS         103.1         116.3         145.9         216.6         236.8           Valuation ratios (x)           P/E         38.0         81.7         63.0         39.9         30.8           P/B         4.7         4.3         4.7         2.9         2.6           EV/EBITDA         20.2         29.0         28.2         18.9         15.0           Leverage ratios (x)         5         0.0         0.0         (0.1         0.1           Net debt/Equity         (0.0)         0.0         0.0         (0.1)         (0.1)           Net debt/EBITDA         (0.0)         0.1         0.1         (0.9)         (0.8)           Int coverage         16.7	EBITDA margin	11.9	7.4	9.7	9.5	9.4
RoCE         18.1         9.5         12.2         10.9         11.2           RoE         13.2         5.6         8.3         8.8         8.9           Per share values           EPS         12.7         6.1         10.9         15.6         20.2           CEPS         19.2         13.3         18.5         26.0         32.7           BVPS         103.1         116.3         145.9         216.6         236.8           Valuation ratios (x)           P/E         38.0         81.7         63.0         39.9         30.8           P/B         4.7         4.3         4.7         2.9         2.6           EV/EBITDA         20.2         29.0         28.2         18.9         15.0           Leverage ratios (x)         2         2         2.0         2         18.9         15.0           Debt/ Equity         0.1         0.1         0.1         0.1         0.1         0.1           Net debt/EBITDA         (0.0)         0.0         0.0         (0.1)         (0.1)         0.1           Int coverage         16.7         4.7         13.8         14.6         18.6	EBIT margin	9.1	4.6	7.1	6.7	6.8
RoE         13.2         5.6         8.3         8.8         8.9           Per share values           EPS         12.7         6.1         10.9         15.6         20.2           CEPS         19.2         13.3         18.5         26.0         32.7           BVPS         103.1         116.3         145.9         216.6         236.8           Valuation ratios (x)           P/E         38.0         81.7         63.0         39.9         30.8           P/B         4.7         4.3         4.7         2.9         2.6           EV/EBITDA         20.2         29.0         28.2         18.9         15.0           Leverage ratios (x)         5.0         0.1         0.1         0.1         0.1           Net debt/Equity         0.1         0.1         0.1         0.1         0.1           Net debt/EBITDA         (0.0)         0.1         0.1         0.0         0.8           Int coverage         16.7         4.7         13.8         14.6         18.6           NWC days           Receivables         33         26         29         29         29           Inventory	PAT margin	6.3	2.6	4.3	4.7	4.8
Per share values           EPS         12.7         6.1         10.9         15.6         20.2           CEPS         19.2         13.3         18.5         26.0         32.7           BVPS         103.1         116.3         145.9         216.6         236.8           Valuation ratios (x)           P/E         38.0         81.7         63.0         39.9         30.8           P/B         4.7         4.3         4.7         2.9         2.6           EV/EBITDA         20.2         29.0         28.2         18.9         15.0           Leverage ratios (x)           Debt/ Equity         0.1         0.1         0.1         0.1           Net debt/Equity         0.0         0.0         0.0         (0.1)         (0.1)           Net debt/EBITDA         (0.0)         0.1         0.1         (0.9)         (0.8)           Int coverage         16.7         4.7         13.8         14.6         18.6           NWC days         8         29         29         29         29         29         29         29         29         29         29         29         29         29         29 <td>RoCE</td> <td>18.1</td> <td>9.5</td> <td>12.2</td> <td>10.9</td> <td>11.2</td>	RoCE	18.1	9.5	12.2	10.9	11.2
EPS         12.7         6.1         10.9         15.6         20.2           CEPS         19.2         13.3         18.5         26.0         32.7           BVPS         103.1         116.3         145.9         216.6         236.8           Valuation ratios (x)           P/E         38.0         81.7         63.0         39.9         30.8           P/B         4.7         4.3         4.7         2.9         2.6           EV/EBITDA         20.2         29.0         28.2         18.9         15.0           Leverage ratios (x)         5         0.1         0.1         0.1         0.1         0.1           Net debt/Equity         (0.0)         0.0         0.0         (0.1)         (0.1)           Net debt/EBITDA         (0.0)         0.1         0.1         0.9)         (0.8)           Int coverage         16.7         4.7         13.8         14.6         18.6           NWC days         2         29         29         29         29         29           Inventory         84         90         102         102         102         102	RoE	13.2	5.6	8.3	8.8	8.9
CEPS         19.2         13.3         18.5         26.0         32.7           BVPS         103.1         116.3         145.9         216.6         236.8           Valuation ratios (x)           P/E         38.0         81.7         63.0         39.9         30.8           P/B         4.7         4.3         4.7         2.9         2.6           EV/EBITDA         20.2         29.0         28.2         18.9         15.0           Leverage ratios (x)         3.0         0.1         0.1         0.1         0.1         0.1           Net debt/Equity         (0.0)         0.0         0.0         (0.1)         (0.1)           Net debt/EBITDA         (0.0)         0.1         0.1         (0.9)         (0.8)           Int coverage         16.7         4.7         13.8         14.6         18.6           NWC days           Receivables         33         26         29         29         29           Inventory         84         90         102         102         102         102	Per share values					
BVPS         103.1         116.3         145.9         216.6         236.8           Valuation ratios (x)         81.7         63.0         39.9         30.8           P/B         4.7         4.3         4.7         2.9         2.6           EV/EBITDA         20.2         29.0         28.2         18.9         15.0           Leverage ratios (x)         Debt/ Equity         0.1         0.1         0.1         0.1           Net debt/Equity         (0.0)         0.0         0.0         (0.1)         (0.1)           Net debt/EBITDA         (0.0)         0.1         0.1         (0.9)         (0.8)           Int coverage         16.7         4.7         13.8         14.6         18.6           NWC days         Receivables         33         26         29         29         29           Inventory         84         90         102         102         102	EPS	12.7	6.1	10.9	15.6	20.2
Valuation ratios (x)         P/E       38.0       81.7       63.0       39.9       30.8         P/B       4.7       4.3       4.7       2.9       2.6         EV/EBITDA       20.2       29.0       28.2       18.9       15.0         Leverage ratios (x)         Debt/ Equity       0.1       0.1       0.1       0.1       0.1         Net debt/Equity       (0.0)       0.0       0.0       (0.1)       (0.1)         Net debt/EBITDA       (0.0)       0.1       0.1       (0.9)       (0.8)         Int coverage       16.7       4.7       13.8       14.6       18.6         NWC days         Receivables       33       26       29       29       29         Inventory       84       90       102       102       102	CEPS	19.2	13.3	18.5	26.0	32.7
P/E         38.0         81.7         63.0         39.9         30.8           P/B         4.7         4.3         4.7         2.9         2.6           EV/EBITDA         20.2         29.0         28.2         18.9         15.0           Leverage ratios (x)         Debt/ Equity         0.1         0.1         0.1         0.1         0.1           Net debt/Equity         (0.0)         0.0         0.0         (0.1)         (0.1)           Net debt/EBITDA         (0.0)         0.1         0.1         (0.9)         (0.8)           Int coverage         16.7         4.7         13.8         14.6         18.6           NWC days           Receivables         33         26         29         29         29           Inventory         84         90         102         102         102	BVPS	103.1	116.3	145.9	216.6	236.8
P/B         4.7         4.3         4.7         2.9         2.6           EV/EBITDA         20.2         29.0         28.2         18.9         15.0           Leverage ratios (x)         USAN METRIC (x)           Debt/ Equity         0.1         0.1         0.1         0.1         0.1           Net debt/Equity         (0.0)         0.0         0.0         (0.1)         (0.1)           Net debt/EBITDA         (0.0)         0.1         0.1         (0.9)         (0.8)           Int coverage         16.7         4.7         13.8         14.6         18.6           NWC days           Receivables         33         26         29         29         29           Inventory         84         90         102         102         102	Valuation ratios (x)					
EV/EBITDA       20.2       29.0       28.2       18.9       15.0         Leverage ratios (x)       Use of the property of the prope	P/E	38.0	81.7	63.0	39.9	30.8
Leverage ratios (x)           Debt/ Equity         0.1         0.1         0.1         0.1         0.1         0.1         0.1         0.1         0.1         0.1         0.1         0.1         0.1         (0.1)         (0.1)         0.1         0.1         0.9         (0.8)         0.8         0.0         0.0         0.0         0.0	P/B	4.7	4.3	4.7	2.9	2.6
Debt/ Equity         0.1         0.1         0.1         0.1         0.1           Net debt/Equity         (0.0)         0.0         0.0         (0.1)         (0.1)           Net debt/EBITDA         (0.0)         0.1         0.1         (0.9)         (0.8)           Int coverage         16.7         4.7         13.8         14.6         18.6           NWC days           Receivables         33         26         29         29         29           Inventory         84         90         102         102         102	EV/EBITDA	20.2	29.0	28.2	18.9	15.0
Net debt/Equity         (0.0)         0.0         0.0         (0.1)         (0.1)           Net debt/EBITDA         (0.0)         0.1         0.1         (0.9)         (0.8)           Int coverage         16.7         4.7         13.8         14.6         18.6           NWC days           Receivables         33         26         29         29         29           Inventory         84         90         102         102         102	Leverage ratios (x)					
Net debt/EBITDA         (0.0)         0.1         0.1         (0.9)         (0.8)           Int coverage         16.7         4.7         13.8         14.6         18.6           NWC days           Receivables         33         26         29         29         29           Inventory         84         90         102         102         102	Debt/ Equity	0.1	0.1	0.1	0.1	0.1
Int coverage         16.7         4.7         13.8         14.6         18.6           NWC days         Section of the control of t	Net debt/Equity	(0.0)	0.0	0.0	(0.1)	(0.1)
NWC days           Receivables         33         26         29         29         29           Inventory         84         90         102         102         102	Net debt/EBITDA	(0.0)	0.1	0.1	(0.9)	(0.8)
Receivables         33         26         29         29         29           Inventory         84         90         102         102         102	Int coverage	16.7	4.7	13.8	14.6	18.6
Inventory 84 90 102 102 102	NWC days					
•	Receivables	33	26	29	29	29
Payables 35 62 85 85 85	Inventory	84	90	102	102	102
	Payables	35	62	85	85	85




Exhibit 15: 1-year forward P/E (x) chart



Source: Company, YES Sec

#### **Recommendation Tracker**





#### STANDARD DISCLAIMER:

YES Securities (India) Limited, Registered Address: 2<sup>nd</sup> Floor, North Side, YES BANK House, Off Western Express Highway, Santacruz East, Mumbai - 400055. Maharashtra, India | Correspondence Add: 7<sup>th</sup> Floor, Urmi Estate Tower A, Ganpatrao Kadam Marg, Opp. Peninsula Business Park, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. | Website: www.yesinvest.in | Email: customer.service@ysil.in

Registration Nos.: CIN: U74992MH2013PLC240971 | SEBI Registration No.: NSE, BSE, MCX & NCDEX : INZ000185632 | Member Code: BSE - 6538, NSE - 14914, MCX - 56355 & NCDEX - 1289 | CDSL & NSDL: IN-DP-653-2021 | RESEARCH ANALYST: INH000002376 | INVESTMENT ADVISER: INA000007331 | Sponsor and Investment Manager to YSL Alternates Alpha Plus Fund (Cat III AIF) and YES Wealth Maximiser AIF (Cat III AIF) SEBI Registration No.: IN/AIF3/20- 21/0818 | AMFI ARN Code - 94338

Details of Compliance Officer: Aditya Goenka | Email: compliance@ysil.in / Contact No.: 022-65078127 | Grievances Redressal Cell: customer.service@ysil.in / igc@ysil.in

Standard Disclaimer: Investment in securities market are subject to market risks; read all the related documents carefully before investing. Above representation provides an overview related to our past performance neither does it provide any guarantee of future performance, nor we are ensuring any guaranteed returns. Actual Client returns may vary depending upon time premium, volatility Index, intrinsic value of the script, open interest, other geopolitical conditions and choice of the customer to execute the recommendation in full or part. All recommendations are published under Research Analyst License of YES Securities (India) Limited (YSIL); execution of the recommendation is at complete discretion of customer without any intervention by the research publisher.

Contents which are exclusively for Non-Broking Products/Services e.g. Mutual Fund, Mutual Fund-SIP, Research reports, Insurance, etc. where the YSIL is just a distributor. These are not Exchange traded product and the YSIL is just acting as distributor. Kindly note that all disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism.

YSIL is a wholly owned subsidiary of YES Bank Limited. Savings, Current, PIS and Demat Account are offered by YES Bank Limited. Please note Brokerage would not exceed the SEBI prescribed limit. YSIL also acts in the capacity of distributor for Products such as IPOs, Mutual Funds, Mutual Fund-SIPs, NCD/Bonds, etc., All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism.

Margin Trading Funding (MTF) is an exchange approved product offered to YSIL trading account holders, as per the regulation and guideline of SEBI Circular: CIR/MRD/DP/54/2017 dated June 13, 2017. For product specification, T&C, rights and obligations statement issued by the YSIL visit https://yesinvest.in/standard\_documents\_policies

#### DISCLAIMER

Investments in securities market are subject to market risks, read all the related documents carefully before investing.

The information and opinions in this report have been prepared by YSIL and are subject to change without any notice. The report and information contained herein are strictly confidential and meant solely for the intended recipient and may not be altered in any way, transmitted to, copied or redistributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of YSIL.

The information and opinions contained in the research report have been compiled or arrived at from sources believed to be reliable and have not been independently verified and no guarantee, representation of warranty, express or implied, is made as to their accuracy, completeness, authenticity or validity. No information or opinions expressed constitute an offer, or an invitation to make an offer, to buy or sell any securities or any derivative instruments related to such securities. Investments in securities are subject to market risk. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. Investors should note that Price of each of the securities or value may rise or fall and, accordingly, investors may even receive amounts which are less than originally invested. The investor is advised to take into consideration all risk factors including their own financial condition, suitability to risk return profile and the like, and take independent professional and/or tax advice before investing. Opinions expressed are our current opinions as of the date appearing on this report. Investor should understand that statements regarding future prospects may not materialize and are of general nature which may not be specifically suitable to any particular investor. Past performance may not necessarily be an indicator of future performance. Actual results may differ materially from those set forth in projections. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. YES Securities (India) Limited conforms with the rules and regulations enumerated in the Securities and Exchange Board of India (Research Analysts) Regulations, 2014 as amended from time to time.

Technical analysis reports focus on studying the price movement and trading turnover charts of securities or its derivatives, as opposed to focusing on a company's fundamentals and opinions, as such, may not match with reports published on a company's fundamentals.

YSIL, its research analysts, directors, officers, employees and associates accept no liabilities for any loss or damage of any kind arising out of the use of this report. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject YSIL and associates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.



YES Securities (India) Limited distributes research and engages in other approved or allowable activities with respect to U.S. Institutional Investors through Rule 15a-6 under the Securities Exchange Act of 1934 (the "Exchange Act")<sup>[1]</sup> and regulations under an exclusive chaperone arrangement with Brasil Plural Securities LLC. The views and sentiments expressed in this research report and any findings thereof accurately reflect YES Securities (India) Limited analyst's truthful views about the subject securities and or issuers discussed herein. YES Securities (India) Limited is not registered as a broker-dealer under the Securities Exchange Act of 1934, as amended (the "Exchange Act") and is not a member of the Securities Investor Protection Corporation ("SIPC"). Brasil Plural Securities LLC is registered as a broker-dealer under the Exchange Act and is a member of SIPC. For questions or additional information, please contact Gil Aikins (gil.aikins@brasilplural.com) or call +1 212 388 5600.

This research report is the product of YES Securities (India) Limited. YES Securities (India) Limited is the employer of the research analyst(s), the authors of this research report. YES Securities (India) Limited is the concerned representatives (employees) of YES Securities (India) Limited, are responsible for the content of this research report including but not limited to any material conflict of interest of YES Securities (India) Limited in relation the issuer(s) or securities as listed in this research report. This YES Securities (India) Limited research report is distributed in the United States through Brasil Plural Securities LLC (BPS). The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and is/ are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. As per SEC Rule 15a-6, the U.S. broker-dealer must accompany any third party research report it distributes with, or provide a web address that directs a recipient to, disclosure of any material conflict of interest that can reasonably be expected to have influenced the choice of a third-party research report provider or the subject company of a third-party research.

FINRA Rules 2241 and 2242, which govern the conduct of research analysts and the content of equity and debt research reports, respectively, apply to all research distributed by a FINRA member firm, including research prepared by a foreign broker-dealer under Rule 15a-6.

- Research reports prepared by a foreign broker-dealer and distributed by a U.S. broker-dealer are deemed to be third party
  research reports, as reports produced by a person other than a FINRA member.
- Prior to distributing any third party research, a U.S. broker-dealer must assure that such report contains the required disclosures under FINRA Rule 2241(h) or 2242(g)(3), as applicable.

This report is intended for distribution by YES Securities (India) Limited only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). As per Rule 15a-6(b)(4) of the Exchange Act, 1934, "Major U.S. institutional investor" means a U.S. institutional investor with assets, or assets under management, in excess of US\$100 million, or a registered investment adviser with assets under management in excess of US\$100 million. If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person or entity. Transactions in securities discussed in this research report should be effected through Brasil Plural Securities LLC (BPS) or another U.S. registered broker dealer/Entity as informed by YES Securities (India) Limited from time to time.

In adopting Rule 15a-6, the SEC sought "to facilitate access to foreign markets by U.S. institutional investors through foreign broker-dealers and the research that they provide, consistent with maintaining the safeguards afforded by broker-dealer registration." [Rule 15a-6 Adopting Release at 54 FR 30013; see also Registration Requirements for Foreign Broker-Dealers, Exchange Act Release No. 25801 (June 14, 1988), 53 FR 23645 (June 23, 1988)].

Rule 15a-6 under the Securities Exchange Act of 1934 provides conditional exemptions from broker-dealer registration for foreign broker-dealers that engage in certain specified activities involving U.S. investors. These activities include:

<sup>(</sup>a) Effecting unsolicited securities transactions;

<sup>(</sup>b) Providing research reports to major U.S. institutional investors, and effecting transactions in the subject securities with or for those investors;

<sup>(</sup>c) Soliciting and effecting transactions with or for U.S. institutional investors or major U.S. institutional investors through a "chaperoning broker-dealer"; and

<sup>(</sup>d) Soliciting and effecting transactions with or for registered broker-dealers, banks3 acting in a broker or dealer capacity, certain international organizations, foreign persons temporarily present in the U.S., U.S. citizens resident abroad, and foreign branches and agencies of U.S. persons.



#### **DISCLOSURE OF INTEREST**

Name of the Research Analyst: Udit Gajiwala, Shalin Damani

The analyst hereby certifies that opinion expressed in this research report accurately reflect his or her personal opinion about the subject securities and no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendation and opinion expressed in this research report.

Sr. No.	Particulars	Yes/No
1	Research Analyst or his/her relative's or YSIL's financial interest in the subject company(ies)	No
2	Research Analyst or his/her relative or YSIL's actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of the research report	No
3	Research Analyst or his/her relative or YSIL has any other material conflict of interest at the time of publication of the research report	No
4	Research Analyst has served as an officer, director or employee of the subject company(ies)	No
5	YSIL has received any compensation from the subject company in the past twelve months	No
6	YSIL has received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
7	YSIL has received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
8	YSIL has received any compensation or other benefits from the subject company or third party in connection with the research report	No
9	YSIL has managed or co-managed public offering of securities for the subject company in the past twelve months	No
10	Research Analyst or YSIL has been engaged in market making activity for the subject company(ies)	No

Since YSIL and its associates are engaged in various businesses in the financial services industry, they may have financial interest or may have received compensation for investment banking or merchant banking or brokerage services or for any other product or services of whatsoever nature from the subject company(ies) in the past twelve months or associates of YSIL may have managed or co-managed public offering of securities in the past twelve months of the subject company(ies) whose securities are discussed herein.

Associates of YSIL may have actual/beneficial ownership of 1% or more and/or other material conflict of interest in the securities discussed herein.

#### RECOMMENDATION PARAMETERS FOR FUNDAMENTAL REPORTS

Analysts assign ratings to the stocks according to the expected upside/downside relative to the current market price and the estimated target price. Depending on the expected returns, the recommendations are categorized as mentioned below. The performance horizon is 12 to 18 months unless specified and the target price is defined as the analysts' valuation for a stock. No benchmark is applicable to the ratings mentioned in this report.

BUY: Upside greater than 20% over 12 months

ADD: Upside between 10% to 20% over 12 months

**NEUTRAL:** Upside between 0% to 10% over 12 months

REDUCE: Downside between 0% to -10% over 12 months

SELL: Downside greater than -10% over 12 months

NOT RATED / UNDER REVIEW

Analyst signature Analyst signature

#### **ABOUT YES SECURITIES (INDIA) LIMITED**

YES Securities (India) Limited ("YSIL") is a wholly owned subsidiary of YES BANK LIMITED. YSIL is a Securities and Exchange Board of India (SEBI) registered Stock broker holding membership of National Stock Exchange (NSE), Bombay Stock Exchange (BSE), Multi Commodity Exchange (MCX) & National Commodity & Derivatives Exchange (NCDEX). YSIL is also a SEBI-registered Category I Merchant Banker, Investment Adviser and Research Analyst. YSIL is also a Sponsor and Investment Manager of Alternate Investment Fund - Category III (YSIL Alternates) and AMFI registered Mutual Fund Distributor. The Company is also a registered Depository Participant with CDSL and NSDL. YSIL offers, inter alia, trading/investment in equity and other financial products along with various value added services. We hereby declare that there are no disciplinary actions taken against YSIL by SEBI/Stock Exchanges.